Nanobiotix S.A.

Paris Stock Exchange NANO.PA

Nanobiotix S.A. Operating Income Margin for the year ending December 31, 2023: -89.09%

Nanobiotix S.A. Operating Income Margin is -89.09% for the year ending December 31, 2023, a 91.57% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Nanobiotix S.A. Operating Income Margin for the year ending December 31, 2022 was -1,057.22%, a 99.79% change year over year.
Nanobiotix S.A. Operating Income Margin for the year ending December 31, 2021 was -498,020.00%, a -540.26% change year over year.
Nanobiotix S.A. Operating Income Margin for the year ending December 31, 2020 was -77,784.00%, a -7.52% change year over year.
Nanobiotix S.A. Operating Income Margin for the year ending December 31, 2019 was -72,341.18%, a -8,270.47% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Paris Stock Exchange: NANO.PA

Nanobiotix S.A.

CEO	Mr. Laurent Levy Ph.D.
IPO Date	Oct. 29, 2012
Location	France
Headquarters	60 rue de Wattignies
Employees	110
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Clinical Trials Medical Instruments Pharmaceuticals Vaccines

Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Key trends

Past 5 years